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Structural Rationale for the Broad Neutralization
of HIV-1 by Human Monoclonal Antibody 447-52D
because peptides and protein fragments containing V3
could readily elicit neutralizing antibodies (Goudsmit et
al., 1988; Palker et al., 1988; Rusche et al., 1988). The
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La Jolla, California 92037 tion properties (Gorny et al., 1993, 1997, 2002).
447-52D is a human (IgG3, ) monoclonal antibody3 New York VA Medical Center and
New York University School of Medicine produced by a heterohybridoma derived from peripheral
blood mononucleocytes from a clade B, HIV-1-infectedNew York, New York 10010
individual (Gorny et al., 1993). 447-52D recognizes the
V3 loop; its core epitope has been mapped with overlap-
ping peptides to the highly conserved V3 crown GPxRSummary
(residues 312–315) (Gorny et al., 1992, 1993). Unlike
most V3 antibodies, 447-52D can neutralize both X4 and447-52D is a human monoclonal antibody isolated from
R5 primary viral isolates (Gorny et al., 2002), correlatinga heterohybridoma derived from an HIV-1-infected in-
with its ability to bind V3 peptides with a wide rangedividual. This antibody recognizes the hypervariable
of sequence variability (Zolla-Pazner et al., 1999). Angp120 V3 loop, and neutralizes both X4 and R5 primary
understanding of how 447-52D is able to effect suchisolates, making it one of the most effective anti-V3
unusually broad neutralization for a V3 antibody couldantibodies characterized to date. The crystal structure
facilitate design of an HIV-1 vaccine.of the 447-52D Fab in complex with a 16-mer V3 pep-
Crystal structures have been determined for the coretide at 2.5 A˚ resolution reveals that the peptide  hair-
region of gp120 from HIV-1 viral isolates HXB2 and YU2pin forms a three-stranded mixed sheet with comple-
in complex with CD4 and Fab 17b (Kwong et al., 1998,mentarity determining region (CDR) H3, with most of
2000). As the gp120 cores were extensively modifiedthe V3 side chains exposed to solvent. Sequence spec-
from wild-type by deletion of 52 N- and 19 C-terminal,ificity is conferred through interaction of the type-II
67 V1/V2, and 32 V3 (298–329) residues and by deglyco-turn (residues GPGR) at the apex of the V3 hairpin
sylation, no structural information could be obtained forwith the base of CDR H3. This novel mode of peptide-
V3. However, crystal structures exist for complexes ofantibody recognition enables the antibody to bind to
V3 peptides from the MN viral strain with four differentmany different V3 sequences where only the GPxR
neutralizing antibodies (50.1 [Rini et al., 1993], 59.1[Ghi-core epitope is absolutely required.
ara et al., 1994, 1997], 58.2 [Stanfield et al., 1999], and
83.1 [Stanfield et al., 2003]) derived from immunization of
Introduction mice with V3 peptides. The conformation of V3 peptides
bound to Fabs 50.1 (CKRIHIGPG), 59.1 (IHIGPGRAFYT),
HIV-1 is a membrane-enveloped virus whose outer sur- and 83.1 (KRIHIGPGRA) are all highly similar, with resi-
face contains oligomeric clusters of noncovalently asso- dues KRIHI forming an extended  strand, immediately
ciated glycoproteins gp120 and gp41 (for review see followed by a  turn around GPGR (type II for 50.1 and
Turner and Summers, 1999). The gp120 third hypervari- 59.1, type I for 83.1). The peptide bound to Fab 59.1
able (V3) loop (35 residues) varies extensively in se- continues with a type-I/I double bend consisting of a
quence among different viral strains, but has a region type I turn around GRAF and a type I turn around RAFY.
of relatively conserved residues at the apex or crown The GPGR turn in the Fab 58.2 complex differs from
(GPGR or GPGQ) of the loop and a conserved disulfide that in the other V3 peptides, largely due to different
at its base (Cys296–Cys331; HXB2 numbering). V3 has torsion angles for the first Gly, which cause the peptide
been implicated in many viral functions, including core- backbone to change direction with respect to the struc-
ceptor binding, such as to CCR5 (Cormier et al., 2001; turally conserved KRIHI  strand. Residues GPGR in this
Rizzuto and Sodroski, 1998, 2000) or CXCR4 (Basmacio- latter complex form a type I turn, and GRAF a type VIa turn.
gullari et al., 2002) and for determining cell tropism (for Many NMR studies of V3 peptides in solution have
review see Hoffman and Doms, 1999). Positively charged also been carried out, including two with V3 peptides
residues are frequently found at critical positions in the bound to Fvs. When the V3 peptide from the IIIB isolate
V3 loop in CXCR4-tropic viruses (DeJong et al., 1992) (RKSIRIQRGPGRAFVTIG) binds to murine monoclonal
while neutral or negatively charged residues are found antibody 0.5 (Tugarinov et al., 2000), it forms a hairpin
at these positions in CCR5-tropic viruses (Bhattacharya with an irregular turn around GPGR, while in the MN V3
et al., 1996). V3 is also a major inducing epitope for anti- complex with human antibody 447-52D (Sharon et al.,
HIV-1 antibodies, and was originally termed the “princi- 2003), the peptide forms a  hairpin with a  turn around
pal neutralizing determinant” (Javaherian et al., 1989) GPGR. Extensive NMR studies of isolated V3 peptides
do not indicate any stable structure in solution, although
transient turns were found around the GPGR (Catasti et*Correspondence: wilson@scripps.edu
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Figure 1. Stereo view of the 447-52D Fab
Complex with the V3 Loop Peptide
The C trace of one Fab molecule in the
asymmetric unit of the 447-52D/peptide crys-
tal structure is shown with the light and heavy
chains in light and dark gray, and the bound
V3 peptide in yellow. CDR loops L1, L2, L3,
H1, H2, and H3 are colored dark blue, purple,
dark green, cyan, pink, and light green, re-
spectively. The peptide in combination with
the H3 CDR forms a three-stranded  sheet.
This and subsequent figures were generated
with MOLSCRIPT (Kraulis, 1991) and ren-
dered with RASTER3D (Merritt and Bacon,
1997).
al., 1995, 1996; Chandrasekhar et al., 1991; de Lorimier et IgG3 Fab for which an X-ray structure has been deter-
mined (Figure 1). Not surprisingly, the IgG3 CH1 is struc-al., 1994; Dettin et al., 1993, 1997; Ghiara et al., 1997;
Gupta et al., 1993; Huang et al., 1996, 1997; Markert et turally very similar to the IgG1 CH1 (rmsd of 1.1 A˚ for all
CH1 C atoms of 447-52D and IgG1 HIL [PDB code 8fab])al., 1996; Sarma et al., 1997; Vranken et al., 1996; Vu et al.,
1996, 1999; Zvi et al., 1992). Addition of 20%TFE (Catasti as only 4 residues differ (H127, H129, H207, and H222).
et al., 1995, 1996; Chandrasekhar et al., 1991; Vranken
et al., 1996; Zvi et al., 1992) usually stabilizes an -helical
conformation immediately C-terminal to GPGR. NMR
studies on peptides modified by cyclization (Cabezas
et al., 2000; Chandrasekhar et al., 1991; Gupta et al.,
1993; Huisman et al., 2000; Tolman et al., 1993; Vranken
et al., 1995, 1996, 2001), by replacement of Ala316 with
the conformationally restricted residue -aminoisobutyric
acid (Cabezas et al., 2000; Ghiara et al., 1997), by glyco-
sylation (Huang et al., 1996, 1997; Markert et al., 1996),
through attachment to resin beads (Jelinek et al., 1997a),
through attachment to a bacteriophage viral coat protein
(Jelinek et al., 1997b), and through attachment to carrier
proteins, such as BPTI (Wu et al., 2000) and MUC1 (Fon-
tenot et al., 1995), all show an increased  turn propen-
sity around GPGRAF. Significantly, V3 peptides
attached to filamentous bacteriophage fd viral coat pro-
tein pVIII (Jelinek et al., 1997b) adopt a double-turn
structure similar to that observed in the Fab 59.1-pep-
tide crystal structure (Ghiara et al., 1994, 1997).
We report here the crystal structure at 2.5 A˚ resolution
of Fab 447-52D in complex with a clade B V3 peptide
that represents the first structural example of an anti-
V3 antibody with neutralizing activity against a number
of X4 and R5 primary isolates. In addition, the Fab con-
Figure 2. Comparison of Fab L3 CDR with Other Canonical L3 CDRstains a CDR L3 of a previously unclassified length (3
(A) New L3 CDR structure. The 447-52D L3 (salmon) is shown super-amino acid insertion after L95), thus providing a new
imposed on loops from HC19 and CHA255 (1gig, 1ind; yellow;canonical structure for L3.
Chothia class L3-1A), NEW (7fab; purple; class L3-1B), SE155
(1mfa; cyan; class L3-1C), and KOL (2fb4; blue; class L3-2). The
Results and Discussion class L3-1 loops have no insertions after residue 95, the class
L3-2 loops have two insertions after residue 95, and 447-52D has
three insertions after residue 95, making it the longest L3 loop seenFab Structure
thus far in an Fab structure.The crystallographic asymmetric unit contains two Fab/
(B) Conformational changes in 447-52D L3 side chains. The 447-peptide complexes related by a noncrystallographic 2-fold
52D L3 CDR loop (salmon) is shown superimposed on the 11 otheraxis. Both complexes are very similar, and unless noted
L3 loops (yellow) containing Trp at positions L91 and L96 (PDB
otherwise, discussion will focus only on the first mole- codes 1a6u, 1dl7, 1etz, 1f4w, 1gig, 1ind, 1mfa, 1ngp, 1sm3, 1yuh,
cule. The Fab light and heavy chains will be identified and 2vir). The side chain positions for these Trp residues differ in
447-52D, possibly as a result of peptide binding.by L and H, the peptide by P. 447-52D is the first human
X-Ray Crystal Structure of Fab 447-52D V3 Complex
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Figure 3. Comparison of H3 Loops with
Kinked and Extended Bases
(A) This stereo view of the 447-52D H3 shows
that its base is “kinked,” contrary to the pre-
diction from its sequence. The 447-52D
AspH101 points away from the TrpH103 side
chain, allowing TrpH103 N1 to hydrogen
bond to the AspH101 backbone carbonyl
oxygen.
(B) The CDR H3 of Jel103 (PDB code 1mrc)
forms an extended base, where the AspH101
side chain hydrogen bonds to the TrpH103
N1 atom.
The elbow angles for the two 447-52D Fab molecules GluH100e and extends out approximately 25 A˚ from the
antibody combining site (Figure 1). The residue typesare 208 and 204. Two residues fall in the disallowed
regions of the Ramachandran plot: AsnL51 is in a highly found at H93, H94, and H101 (Thr, Thr, Asp) predict an
extended structure for the base of the 447-52D H3conserved  turn in almost all antibodies and represents
the major canonical structure for CDR L2 (Al-Lazikani (Morea et al., 1998; Shirai et al., 1996) rather than the
“kinked” conformation found here (Figure 3). The sideet al., 1997), and Asp L151 is at the tip of an exposed loop.
CDR’s L1 and L2 belong to canonical classes L1-1 chain of AspH101 normally hydrogen bonds to TrpH103N1,
but in 447-52D, AspH101 points away from Trp, and theand L2-2 (Al-Lazikani et al., 1997; Martin and Thornton,
1996). However, L3 (with a 3 residue insertion after resi- preceding backbone carbonyl oxygen hydrogen bonds
to TrpH103N1. The AspH101 position is stabilized by a hy-due 95) is longer than previously classified loops. A
comparison of L3 with those of classes L3-1 (no inser- drogen bond between AspH101O1 and TyrH100kOH. At
least three other Fabs also have kinked bases not pre-tions after L95) and L3-2 (two insertions after L95) is
shown in Figure 2A. Other interesting features of the dicted by their sequence: Fab 26-10 (1igj [Jeffrey et al.,
1993]) containing AlaH93, GlyH94, and AspH101; Fab B02C11447-52D L3 are the unusual side chain dispositions of
TrpL91 and TrpL96 (Figure 2B). TrpL91 usually has side chain (1iqd [Spiegel et al., 2001]) with AlaH93, ValH94, and AspH101;
and Fab 83.1 with AlaH93, IleH94, and AspH101 (Stanfield ettorsion angles of 1  180, 2  	90, but in 447-52D
these are 1  60, 2  90. TrpL96 maintains the same al., 2003).
rotamer, but shifts slightly from its usual position. In the
447–52D complex, ProP313 is sandwiched between TrpL91 Peptide Structure
The 16-mer peptide used for cocrystallization (CKRIHIGand TrpL96, suggesting that these Trp side chains may
have rearranged to accommodate peptide binding. PGRAFYTTC-NH2; 304–309, 312–321; peptide number-
ing according to HXB2 [Ratner et al., 1987]) correspondsThe H1 and H2 CDRs belong to canonical classes 1
and 4, as expected from their length and sequence. The to the MN V3 sequence. Residues P305–P316 (KRIHIGP
GRA) can be clearly interpreted in the electron densitylong H3 CDR (20 residues in length [DGFIMIRGVSEDYY
YYYMDV; H95-H102]) forms a regular  hairpin with a maps (Figure 4A) except for the LysP305 side chain. Weak
electron density corresponding to three additional resi-type I turn around residues GlyH100b-ValH100c-SerH100d-
Structure
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Figure 4. Electron Density for the V3 Peptide
Bound to 447-52D
(A) This stereo view shows the SA 2Fo-Fc elec-
tron density (cyan) after refinement, con-
toured at 1.5
 around the V3 peptide (yellow)
for the first molecule in the asymmetric unit.
Side chain atoms are not included in the
model for residue LysP305 due to weak electron
density for its side chain.
(B) Additional density for three more residues
is visible when contoured at 0.7
 and would
extend the  sheet to four strands. Our best
interpretation of that density is shown in
black, but these residues have not been in-
cluded in the final model. Electron density is
shown for only this area for clarity. Attempts
to improve the density, such as NCS averag-
ing, were not successful. This figure was gen-
erated with BOBSCRIPT (Esnouf, 1999) and
rendered as in Figure 1.
dues at the C terminus (FYT; P317–P319) (Figure 4B) AspH100fO-IleP307N, 2.6;2.9 A˚; TyrH100hN-IleP307O; 2.7;2.8 A˚;
TyrH100hO-IleP309N, 2.6;2.9 A˚; TyrH100jN-IleP309O, 3.0;3.1 A˚).was found, but despite repeated attempts to extend
the model (see Experimental Procedures section), these ArgP315 makes cation- interactions with TrpH33 and
TyrH100j, where Arg N is 3.8 A˚ from the center of theresidues could not be positioned with confidence and
are not included in the final model. TyrH100j ring and 3.6–3.8 A˚ from the center of the aromatic
ring of the TrpH33 indole (Figure 6B). The ArgP315 guanadi-Peptide residues KRIHI form an extended  strand,
followed by a type II  turn around GPGR (Figure 5). The nium moiety is nearly coplanar with the TrpH33 indole
(interplanar angle of 11;16) and TyrH100j ring (7;13).peptide strand surprisingly forms extensive main chain
interactions with CDR H3 resulting in a three-stranded Hydrophobic interactions are made by IleP307 and IleP309
with Fab residues Tyr H100i and TyrH100g (Figure 6A). Themixed  sheet, with an up/down/down topology (Figures
5A and 5B) and a standard left-handed twist (Figure 5C). ProP313 side chain in the GPGR turn is about 3.6 A˚ from the
TrpL91 indole, with the rings nearly coplanar (interplanarThe  sheet has one largely polar face consisting of
PheH97, MetH99, ArgH100a, AspH100f, TyrH100h, TyrH100j, ArgP306, angle of 7;7), and about 3.7 A˚ from TrpL96 with the
respective rings nearly perpendicular (interplanar angleHisP308, and ArgP315, and, on the other side, a more hy-
drophobic face coated by the side chains of IleH98, IleH100, of 76;80) (Figure 6B).
In the Fab-peptide complex, molecular surface areasTyrH100g, TyrH100i, IleP307, and IleP309 (Figure 5D).
Six hydrogen bonds and one salt bridge are made be- of 555;585 A˚2 (molecule 1;molecule 2) are buried on the
Fab and 478;494 A˚2 on the peptide. The majority (77%)tween peptide and Fab 447-52D, all to CDR H3. The salt
bridge between AspH95 O2 and ArgP315 NH1 (3.3;3.4 A˚; of the buried Fab surface is contributed by the heavy
chain (59% from H3), and is composed mainly of Tyr,molecule 1 and molecule 2) anchors the peptide to the
base of H3. The only side chain hydrogen bond is be- Trp, Asp, and Glu side chains (43%, 30%, 9%, and 8%
of the surface, respectively). The peptide fits snugly intotween TyrH100j OH and HisP308 N1 (3.0;3.1 A˚) (Figure 6A).
The remaining five hydrogen bonds are between the pep- its binding site, with only one unfilled cavity near IleP309
(Figure 7A). A total of 116;162 van der Waals contactstide main chain atoms and the Fab CDR H3 main chain
in the  sheet interaction (AspH100fN-LysP305O, 3.4;3.4 A˚; are made between peptide and Fab, with the majority
X-Ray Crystal Structure of Fab 447-52D V3 Complex
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Figure 5. Architecture of the CDR H3/V3
Mixed Sheet
(A) The H3 CDR (blue) and the V3 peptide
(yellow) form a mixed  sheet with up-down-
down topology (starting from the H3 N ter-
minus).
(B) The same view of the H3/V3 sheet, with
hydrogen bonds shown.
(C) The sheet has a left-handed twist, with
about 25 rotation between each strand.
(D) A stereo view of the mixed sheet, showing
all side chains. Note the internal pseudo-sym-
metry where H3 residues IleH98, MetH99, IleH100,
and ArgH100a “mirror” peptide residues IleP309,
HisP308, IleP307, and ArgP306 across the C-ter-
minal strand of H3.
from H3 (55%;43%), L3 (20%;33%), and H1 (21%;20%), structure, where the highly conserved  turn crown
and few to no interactions with L1 (2%;4%), H2 (1%;0%), (GPGR) is inserted into the heart of the 447-52D combin-
and L2 (0%;0%) (Figure 6A). The differences in the van ing site, with its extended region (KRIHI) interacting with
der Waals contacts in the two complexes are due to a antibody through extensive main chain hydrogen bond-
slight variation in the position of the peptide (0.5 A˚) ing to the CDR H3 backbone, resulting in a composite
relative to each Fab (Figure 7B). Otherwise, the struc- three-stranded  sheet. Thus, main chain interactions
tures are very similar as reflected by corresponding dominate peptide binding to 447-52D, so that side chain
rmsds in C position for VL, VH (H1–H113) and peptide substitutions at many positions in the peptide can easily
(P305–P316) of 0.12, 0.22, and 0.77 A˚, respectively, when be accommodated. Specific interactions with ProP313 and
the VL domains (L1–L107) are superimposed. The corre- ArgP315 at the base of the binding site likely confer speci-
sponding superposition on VH domains results in rmsds ficity for V3-like sequences despite the nonspecific na-
in C for VL, VH, and peptide of 0.23, 0.12, and 0.64 A˚, ture of the main chain interactions. This conclusion is
respectively. also consistent with screening of 447-52D against a 15-
mer phage-display library (Keller et al., 1993), which
showed that of 55 binding peptides, Gly, Pro, and ArgPeptide Binding Motif
were always selected at P312, P313, and P315, respec-Previous epitope analysis using overlapping peptides
tively. On the other hand, 447-52D could bind peptidesindicated that the core epitope of 447-52D was GPxR
(Gorny et al., 1992) which agrees well with the crystal with many different residues at P308, with the most
Structure
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Figure 6. Stereo view of the Fab 447-52D An-
tigen Binding Site
(A) As in all figures except Figure 1, the Fab
light and heavy chains are depicted in salmon
and blue, with the bound peptide in yellow.
The side chains of the Fab residues in contact
with peptide are shown in a ball-and-stick
representation.
(B) A magnified view of the cation- and salt
bridge interactions between peptide and Fab.
The V3 peptide residue ArgP315 forms a salt
bridge with AspH95, and makes cation- inter-
actions with the side chains of TyrH100j and
TrpH33. Peptide residue ProP313 is nestled into a
cleft formed by Fab residues TrpL91 and TrpL96,
with the Pro ring nearly coplanar to the TrpL91
indole.
frequent being Leu (15/55), His (9/55), Phe (6/55), Arg place. Otherwise, no strong preferences are found at
positions prior to P308 or after P316. Thus, it appears(5/55), and Tyr (5/55), indicating that the HisP308 hydrogen
bond seen in the crystal structure is not critical for pep- that only the V3 GPxR crown residues are highly re-
stricted in sequence preference, with little or no specifictide binding to 447-52D. However, position P309 is more
restricted to hydrophobic residues, with Phe (17/55), Tyr requirements at other positions. The strong preference
for Arg at position P315 is also in agreement with neutral-(12/55), Ile (8/55), Val (7/55), and Leu (7/55) appearing
most frequently. At P314, Gly (30/55) and Ala (10/55) are ization data, where the nonclade B primary isolates that
are neutralized by 447-52D retain an Arg at this positionstrongly preferred, but Ser, His, Lys, Leu, Asn, Gln, and
Arg can also be tolerated in the phage display peptides. (Conley et al., 1994; our unpublished data). However,
most non-B viruses have a Gln at position P315, and itA slight preference is found for Gly (11/55) at position
316, although perhaps surprisingly, many other residues is not yet clear whether the Gln substitution in the V3
crown can be recognized by 447-52D.are tolerated. GlyP316 (the i2 residue in the type II 
turn) has torsion angles of φ  74,   5, in the left-
handed -helical region of the Ramachandran plot. Conserved V3 Structure
447-52D, 50.1, 59.1, and 83.1 are all independently de-Thus, substitution at P316 with a non-Gly residue might
be expected to change the turn type by flipping the rived anti-V3 antibodies and differ in their gp120 reactiv-
ity and virus neutralization profiles. Nevertheless, theP316 carbonyl. The carbonyl makes no hydrogen bonds
to the antibody in the present structure, and there is conformations of the overlapping V3 peptide segments
in the various antibody-peptide structures are all veryample room to accommodate this flip should it take
Figure 7. Antigen Binding Site
(A) The binding surface on Fab 447-52D for
V3. The molecular surface (calculated with
GRASP [Nicholls et al., 1991]) within 6.5 A˚ of
the bound peptide is colored by electrostatic
potential (contoured between	15 and 15 kT).
While the GPGR tip of the peptide is bound
into a pocket in the antibody-combining site,
the other side chains are exposed to solvent
or near unfilled pockets in the surface.
(B) Small difference in V3 peptide binding to
antibody. After superposition of the two Fab
variable domains in the crystal asymmetric
unit, the V3 peptides (dark and light yellow)
differ slightly in their bound positions.
X-Ray Crystal Structure of Fab 447-52D V3 Complex
199
similar (Figure 8). The rmsds (C atoms) for the 447-52D
V3 peptide when compared to peptides bound to 50.1,
59.1, and 83.1 are 1.1 A˚ (for the eight residues in common
with 50.1), 1.2 A˚ (seven in common with 59.1), and 2.6 A˚
(ten in common with 83.1) respectively. Antibody 50.1
(epitope CKRIHIGPG) is extremely specific for MN-like
viral strains, whereas 59.1 (epitope IGPGRAFYT) can
neutralize both MN and IIIB strains, probably because
its epitope starts immediately after the IIIB QR insertion.
Antibody 83.1 (epitope KRIHIGPGRA) has been reported
to also neutralize some R5 primary isolates (SF162, AD-
87), as well as those passaged in cell culture one to two
times (WH89-330) (White-Scharf et al., 1993). Antibody
58.2 (epitope RIHIGPGRAFY) is fairly broad, neutralizing
SF162, AD-87, JR-FL, BaL, WH91-327, WH89-330, WH91-
330, WH189-164, and FDA-300 (White-Scharf et al., 1993).
Interestingly, 58.2 recognizes a second, distinct V3 con-
formation, which differs mainly in the type of  turn
around GPGR, as well as in the main chain torsion angle
for the first Gly residue of the turn, resulting in a strikingly
different disposition of the turn with respect to the
N-terminal extended  strand. Although it is not straight-
forward to correlate the V3 conformations bound to the
different antibodies with their neutralization profiles, it
is striking that the V3 epitopes recognized by 447-52D
and 50.1 are very similar in both conformation and ex-
tent. Yet, 50.1 is highly type specific for TCLA viruses,
while 447-52D can neutralize a number of primary iso-
lates. Thus, the superior breadth of neutralization by
447-52D does not appear to correlate with recognition
of a novel V3 conformation, but rather reflects the unique
mode of antibody-V3 interaction in which only the highly
conserved positions in the crown are required for speci-
ficity. In addition, although the backbone conformation
of V3 bound to 447-52D overlaps well with V3 peptides
bound to 50.1, 59.1, and 83.1, the ArgP315 side chain when
bound to 447-52D is oriented in a different direction. The
side chains of ArgP306, HisP308, and ArgP315 all cluster on
the same face recognized by 447-52D, but ArgP315 is on
the opposite side of the peptide in the other complexes.
Interestingly, these positions are among those impli-
cated as being important in chemokine receptor binding
(Basmaciogullari et al., 2002).
Comparison with NMR Structure
The conformation of a V3 peptide bound to Fv 447-52D
was also recently determined by NMR where unlabeled
447-52D Fv was complexed with 15N- or 13C-labeled 23-
mer MN peptide (YNKRKRIHIGPGRAFYTTKNIIG), and
the V3 peptide conformation derived using TROSY and
standard heteronuclear NMR methods (Sharon et al.,
2003). The major difference between the peptide confor-
views. They include ([A], yellow) the V3 peptide bound to human
Fab 447-52D; ([B], red) V3 peptide bound to murine Fab 50.1 (Rini
et al., 1993); ([C], blue) V3 peptide bound to murine Fab 83.1 (Stan-
field et al., 2003); ([D], gray) V3 peptide bound to murine Fab 59.1
Figure 8. Structures of V3 Peptides (Ghiara et al., 1994, 1997); ([E], blue) V3 peptide bound to murine
These V3 peptide structures were determined by X-ray crystallogra- Fab 58.2 (Stanfield et al., 1999); ([F], purple) V3 peptide bound to
phy (A–E) and NMR (F) in complex with neutralizing Fabs, and as a human Fab 447-52D (NMR) (Sharon et al., 2003); and ([G], black)
virus-chimera (G). Side chains are included to help orient the reader. the truncated V3 loop insertion into a chimeric rhinovirus (Ding et
The top five pairs are each of the same peptide, but in orthogonal al., 2002).
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Figure 9. Stereo view of the Superposition of
the V3 Peptide
Stereo view of the superposition of the V3
peptide (yellow; residues K305–A316) from
the 447-52D Fab/peptide complex with that
previously determined by NMR (purple;
K305–T320, [Sharon et al., 2003]) from a 447-
52D Fv/peptide complex. Although the pep-
tide conformations are similar overall, the
NMR-derived structure shows ordered struc-
ture for a region of the peptide that is less
well ordered in the crystal structure, although
some electron density is present (see Fig-
ure 4B).
mation found in the NMR and X-ray studies is the extent of IGHV3-15*07, IGHJ6*03, and IGHD3-10*01 genes. VL1
genes make up 5 of the 31 functional VL genes, whileof the structured region (KRIHIGPGRAFYTT) found in
the solution study. The four C-terminal residues (FYTT; VH3 genes make up 22 of the 51 functional VH genes.
The 447-52D CDR H3, which makes the majority of inter-P317–P320) in the NMR structure are largely disordered
in the X-ray structure, although weak and broken elec- actions with V3, is derived from the D3-10 segment used
in reading frame 3 (D3  5/25 functional segments) andtron density (Figure 4B) corresponds approximately to
the path taken by the main chain in the NMR structure the JH6 gene segment (JH6  1 out of 6 functional JH
segments).and would extend the mixed  sheet to four strands.
Our provisional interpretation of this disordered region 447-52D has a long CDR H3 of 20 residues in length
(12 residues inserted after H100). H3 loops vary in lengthin the crystal is consistent with the reported NOEs within
this region for ArgP306HN/ThrP319HN, ArgP306HN/ThrP320H, from 2 to 30 residues in human antibodies (1–19 in
mouse) (Collis et al., 2003), but human anti-viral antibod-IleP307H/TyrP318H, and HisP308HN/TyrP318H (equivalent dis-
tances in the X-ray model of 2.6, 4.6, 2.9, and 3.8 A˚). ies frequently have very long CDR H3s, with an average
length of 16.5 residues for 95 analyzed. The CDR H3However, the PheP317 side chain cannot be positioned
in a similar manner in both X-ray and NMR structures. regions of other HIV-1-neutralizing Fabs, such as b12
(18 residues in length), 2F5 (22), X5 (22), and 17b (19),Otherwise, the peptides are similar in their overall fold
(Figure 9), with an rmsd of 1.3 A˚ for the ten C atoms also have long CDR H3s that may allow some of these
antibodies access to recessed regions on the viral gp120(KRIHIGPGRA) used in the superposition.
Although the NMR structure has a  turn around the (Saphire et al., 2001). Whether the long H3 would confer
such an advantage to 447-52D is conjectural at thisGPGR region, compared to a type II  turn in the X-ray
structure, these backbone differences are actually point, as the degree of V3 exposure is unclear, although
some studies suggest that V3 is accessible to manyrather small. The main chain torsion angles for ProP313-
GlyP314 in the NMR and X-ray structures are φ  	72, anti-V3 antibodies (Nyambi et al., 2000; York et al., 2001).
  65; φ  87,   25 (NMR), and φ  	65,  
130; φ  75,   5 (X-ray), and deviate only by slight HIV-1 Vaccine
In conclusion, we have uncovered the structural basisvariations in the positions of the GlyP312 and ProP313 car-
bonyl oxygens (Figure 9). Within the GPGR turn, NOEs for why 447-52D recognizes its V3 epitope in HIV-1
gp120 with unusually broad specificity for a V3 antibody.are reported between ProP312H and ArgP315HN with a
strong sequential interaction between GlyP314HN and A major question is whether an immunogen can now be
designed to elicit this type of antibody response. TheProP313H (Sharon et al., 2003) that are in good agreement
with the corresponding distances of 3.3 and 2.2 A˚ in the germline genes of 447-52D are not unusual, and while
it has been reported that the VH3 family of antibodiestype II  turn of GPGR in the X-ray structure.
decreases in patients during the late stages of HIV-1
infection (David et al., 1996; Scamurra et al., 2000), thisVH and VL Genes
Analysis of the 447-52D gene sequence (http://imgt. should not be a problem in immunizing uninfected indi-
viduals. Immunization with a peptide or peptido-mimeticcines.fr; http://www.mrc-cpe.cam.ac.uk/vbase-ok.php?
menu901) shows that the  light chain is a product of constrained to mimic the V3 conformation recognized by
447-52D might elicit 447-52D-like antibodies, but wouldIGLV1-51*01 and IGLJ3*02 genes, and the heavy chain
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and broad neutralization and to help in the design ofTable 1. Summary of Crystallographic Data
immunogens to induce antibodies with broad and potent
Data Collection neutralizing activity.
Wavelength (A˚) 0.984
Resolution (A˚) 30.0–2.50 (2.54–2.50)a Experimental Procedures
No. of observations 67,571 (3,553)
No. of unique reflections 35,179 (1,816) Fab Production and Purification
Completeness (%) 90.7 (95.2) IgG 447-52D (IgG3, ) was prepared as previously reported (Gorny
Rsymb (%) 7.7 (53.1) et al., 1993). Briefly, peripheral blood cells pooled from two HIV-
Average I/
 13.7 (1.9) 1-infected individuals were transformed and then fused to a human/
mouse hetero-myeloma cell line (SHM-D33). The resulting hetero-Refinement Statistics, all Reflections 0.0
F
hybridoma expressing Mab 447-52D was selected for its ability to
bind a 23-mer peptide corresponding to the V3 sequence of the MNResolution (A˚) 30.0–2.50 (2.59–2.50)
Total no. of reflections 35,173 isolate (YNKRKRIHIGPGRAFYTTKNIIG) and repeatedly cloned until
monoclonality was achieved. Fab fragments were prepared byNo. in test set 1,776
Rcrystc (%) 24.9 (51.0) cleavage of 447-52D IgG with 4% papain in 10 mM L-cysteine for
4 hr, followed by sequential purification of the Fab over Protein A,Rfreed (%) 28.5 (39.2)
No. of Fab atoms 6,672 Superdex 200 (10/30 column, 0.2 M sodium acetate, pH 5.5), and
monoS columns (10/10 column: buffer A  50 mM sodium acetate,No. of peptide atoms 146
No. of waters 53 pH 4.5; buffer B  50 mM sodium acetate, 1 M sodium chloride,
pH 4.5). Human IgG3 Fc regions normally bind poorly to protein A;
Average B Values (A˚2) however, protein A can bind the Fab regions of members of the
human VH3 family (of which 447-52D is a member) through conservedFab 1 variable domain 41
framework residues (Graille et al., 2000).Fab 1 constant domain 46
Fab 2 variable domain 44
Fab 2 constant domain 56 Crystallization and Data Collection
Peptide 1 55 The peptide used for cocrystallization has been previously termed
Peptide 2 58 MP1 (CKRIHIGPGRAFYTTC-NH2; 304–309, 312–322; peptide num-
Waters 34 bering according to the HXB2 reference [Ratner et al., 1987]). The
Wilson B value (A˚2) 57 Fab/peptide complex was prepared by mixing Fab (20 mg/ml) and
Luzzati coordinate error (A˚) 0.40 peptide (10 mg/ml) in a 1:5 molar ratio. Crystals were grown by
sitting drop vapor diffusion with a 1 ml well solution of 1.23 MRamachandran Plot (%)
ammonium sulfate, 0.1 M sodium cacodylate, pH 6.0, and a sample
Most favored 86.6 drop consisting of 0.5 l protein, 0.5 l well solution. The crystals
Additionally allowed 12.6 grow as clusters of thin plates that can be separated prior to mount-
Generously allowed 0.3 ing for data collection. Crystals were cryo protected by brief immer-
Disallowed 0.5e sion in well solution containing 25% glycerol. Diffraction data were
collected at Beamline 11-1 at the Stanford Synchrotron Radiation
Rms Deviations
Laboratory with an ADSC Q315 CCD detector, at a wavelength of
0.984 A˚. The crystal was indexed in monoclinic space group P21Bond lengths (A˚) 0.007
with unit cell dimensions a  76.5 A˚, b  75.4 A˚, c  100.0 A˚,  Angles () 1.4
100.3, with two Fab/peptide complexes in the asymmetric unit, andDihedral () 26.8
a refined mosaicity of 0.65. The Matthews’ coefficient (Matthews,Improper () 0.91
1985) was 2.8 A˚3/Da corresponding to 56% solvent. Data were
a Numbers in parentheses are for the highest resolution shell of data. processed to 2.5 A˚ resolution (Table 1) with the HKL package (Otwi-
b Rsym  hkl|I 	 I|/hklI. nowski and Minor, 1997). In the deposited coordinates, the Fab light
c Rcryst  hkl|Fo 	 Fc|/hkl |Fo|. and heavy chain residues from molecules 1 and 2 are labeled L, H,
d Rfree is the same as Rcryst, but for 5% of the data excluded from the M, and I; the peptide residues are labeled P and Q; and the Fab is
refinement. numbered by the Kabat convention.
e Four residues, but two are in well-defined  turns in most anti-
bodies.
Structure Determination and Refinement
The structure was determined by molecular replacement using Fab
HIL (PDB code 8fab; molecule 2), separated into its variable and
constant domains as search models. HIL is a human (IgG1, ) withcertainly result in a diverse population of V3 antibodies.
sequence identity to 447-52D of 58% and 66% in the Fab variable
To elicit 447-52D-like antibodies, the immunogen must light and heavy chains, respectively. Using the cross-rotation and
induce an immune response that duplicates the main translation routines from AMoRe (Navaza, 1994), the two variable
domain dimers and two constant domain dimers in the asymmetricchain hydrogen bonding observed in this structure,
unit could be oriented and positioned in the unit cell with a correla-avoiding interactions with the majority of the side chains
tion coefficient (CC) and Rcryst of 29.3% and 49.7%, respectively.that would lead to a type-specific response. This may
The two Fab molecules are related by a noncrystallographic 2-foldrequire an immunization regimen that favors the matura-
rotation axis in the xz plane, 60 from z, as expected from the
tion of the antibody response with prolonged intervals presence of a corresponding peak in the MERLOT (Fitzgerald, 1988)
between several doses. The identification of several self-rotation function. Rigid body refinement of the four domains
with AMoRe, using all data from 15 to 4 A˚, resulted in a CC and another anti-V3 monoclonal antibodies with broad neu-
Rcryst of 40.8% and 48.3%, respectively. The Rcryst dropped to 44.5%tralizing activity (Gorny et al., 2002) suggests that this
after rigid body refinement of eight domains (VL, VH, CL, and CH1type of immune response can be obtained. Thus, these
from each Fab) in CNS (Bru¨nger et al., 1998) using all data from 15structural data can now be taken together with results
to 4 A˚. After one round of simulated annealing refinement, the Rcrystof structural studies of the other rare broadly neutralizing and Rfree values were 34.2% and 38.2% at 2.5 A˚ resolution. The
HIV-1 antibodies b12 (Saphire et al., 2001) and 2G12 model was then “mutated” to reflect the proper 447-52D sequence,
and several cycles of model building and positional refinement with(Calarese et al., 2003) to ascertain principles for efficient
Structure
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CNS were carried out. Clear electron density for the bound peptide antigen combining site: correlations between length and sequence
composition of the hypervariable loops and the nature of the antigen.was apparent after the first round of simulated annealing (Figure 4).
Rebuilding was carried out with several different types of electron J. Mol. Biol. 325, 337–354.
density maps including 
A-weighted 2Fo-Fc and Fo-Fc maps, and Conley, A.J., Gorny, M.K., Kessler, J.A., II, Boots, L.J., Ossorio-
2Fo-Fc maps modified by solvent flipping and NCS averaging. Castro, M., Koenig, S., Lineberger, D.W., Emini, E.A., Williams, C.,
Throughout refinement, the VL, VH  peptide, CL, and CH1 atoms and Zolla-Pazner, S. (1994). Neutralization of primary human immu-
were restrained as four individual groups with NCS restraint weights nodeficiency virus type 1 isolates by the broadly reactive anti-V3
of 200. Final refinement statistics are listed in Table 1. As expected monoclonal antibody, 447–52D. J. Virol. 68, 6994–7000.
due to the NCS constraints, the two molecules in the asymmetric
Cormier, E.G., Tran, D.N., Yukhayeva, L., Olson, W.C., and Dragic,
unit are very similar (root mean square deviation [rmsd]) for all C
T. (2001). Mapping the determinants of the CCR5 amino-terminal
atoms is 0.57 A˚). Hydrogen bonds were evaluated with HBPLUS
sulfopeptide interaction with soluble human immunodeficiency virus
(McDonald and Thornton, 1994) and CONTACSYM (Sheriff et al.,
type 1 gp120–CD4 complexes. J. Virol. 75, 5541–5549.
1987), and the electrostatic surface was evaluated with GRASP
David, D., Demaison, C., Bani, L., and Theze, J. (1996). Progressive(Nicholls et al., 1991). Coordinates for V3 peptides in Figure 8 are
decrease in VH3 gene family expression in plasma cells of HIV-from their structures with Fabs 50.1 ( Rini et al., 1993), 83.1 (Stanfield
infected patients. Int. Immunol. 8, 1329–1333.et al., 2003), 59.1 (Ghiara et al., 1997; 1994), 58.2 (Stanfield et al.,
1999), 447-52D (Sharon et al., 2003), and a chimeric rhinovirus (Ding de Jong, J.J., Goudsmit, J., Keulen, W., Klaver, B., Krone, W., Ters-
et al., 2002). mette, M., and de Ronde, A. (1992). Human immunodeficiency virus
type 1 clones chimeric for the envelope V3 domain differ in syncy-
tium formation and replication capacity. J. Virol. 66, 757–765.Acknowledgments
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